Everything you need to Know About Liposome Drug Delivery Technology

Liposomes, a novel drug delivery system (NDDS), are bilayer vesicular structures used in delivering drugs or genetic material into a cell. The aim of NDDS is to deliver the drug at a rate directed by the needs of the body during the period of treatment. Due to the growing number of COVID-19 patients, especially in the US and the European countries, research institutes are pressurized to accelerate their R&D activities to develop drugs and vaccines for the treatment.

To Know More Download Sample PDF

Liposomal drug delivery offers various advantages, such as improved pharmacokinetics and pharmacodynamics, enhanced therapeutic efficacy, and decreased toxicity, thereby making these delivery systems ideal for patients suffering from various chronic conditions. According to the Centers for Disease Control and Prevention (CDC) in 2019, almost 6 in 10 people in the US suffer from at least one chronic disease and 4 in 10 people have two or more chronic diseases.

Over the past few decades, R&D activities in liposomal drug delivery systems have rapidly increased across the world due to increasing prevalence of chronic disease. Drug delivery is the process of administering a pharmaceutical compound to achieve a therapeutic effect in humans.

Cancer is one of the leading causes of death among population worldwide. The American Cancer Society (ACS) estimated that ~1,735,350 new cancer cases were diagnosed in 2018. Targeted drug delivery system (TDDS) delivers the drug in a controlled manner at a preselected biosite. Nanotechnology-based delivery systems are making a significant impact on cancer treatment and the polymers play a key role in the development of nanoparticulate carriers for cancer therapy.

A few major technological advantages involved in the nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved bio-distribution, increased circulation time of the drug, controlled and sustained release of the drug, versatility of route of administration, increased intercellular concentration of drug, and many more. The liposomal carriers utilized in nanotechnology drug delivery systems are likely to experience rapid adoption, which, in turn, is propel the market growth.

Thus, companies in the liposome drug delivery market are capitalizing on this opportunity to increase their research in nanomaterials, such as nanospheres, liposomes, and nanoparticles that are active antiviral agents. Liposome drug delivery is being leveraged with increased in vivo and in vitro drug activities for routine clinical practices.

Major Key Players Involved in this Study

  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Luye Pharma Group
  • Ipsen Pharma
  • CELSION, Inc.
  • Gilead Sciences, Inc.
  • Astellas Pharma, Inc.
  • Johnson & Johnson Services, Inc.
  • Acrotech Biopharma, Inc.